These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 16001959)

  • 1. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
    Delcayre A; Shu H; Le Pecq JB
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexosomes as a cell-free vaccine for cancer immunotherapy.
    Nikfarjam S; Rezaie J; Kashanchi F; Jafari R
    J Exp Clin Cancer Res; 2020 Nov; 39(1):258. PubMed ID: 33228747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexosomes as a therapeutic cancer vaccine: from bench to bedside.
    Le Pecq JB
    Blood Cells Mol Dis; 2005; 35(2):129-35. PubMed ID: 16024263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?
    Viaud S; Théry C; Ploix S; Tursz T; Lapierre V; Lantz O; Zitvogel L; Chaput N
    Cancer Res; 2010 Feb; 70(4):1281-5. PubMed ID: 20145139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Exosomes and anti-tumour immunotherapy].
    Chaput N; Andre F; Schartz NE; Flament C; Angevin E; Escudier B; Zitvogel L
    Bull Cancer; 2003; 90(8-9):695-8. PubMed ID: 14609758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
    Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
    Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes as novel therapeutic nanodevices.
    Delcayre A; Le Pecq JB
    Curr Opin Mol Ther; 2006 Feb; 8(1):31-8. PubMed ID: 16506523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.
    Kvistborg P; Bechmann CM; Pedersen AW; Toh HC; Claesson MH; Zocca MB
    Vaccine; 2009 Dec; 28(2):542-7. PubMed ID: 19837091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanovesicular vaccines: exosomes.
    Li X; Zhang Z; Beiter T; Schluesener HJ
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):329-35. PubMed ID: 16088317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccinal cell therapy in melanoma].
    Quillien V; Lesimple T; Toujas L
    Bull Cancer; 2003; 90(8-9):722-33. PubMed ID: 14609762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity.
    Näslund TI; Gehrmann U; Qazi KR; Karlsson MC; Gabrielsson S
    J Immunol; 2013 Mar; 190(6):2712-9. PubMed ID: 23418627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.